Nicolay Berard-Andersen
CEO
MSc. Biomedical engineering from Stanford University and ETH-Zürich, is a serial entrepreneur with over 25 years experience in the medical device industry. Nicolay co-founded Respinor by combining a novel ultrasound approach with a large unmet medical need within Respiratory care and Mechanical ventilation. His broad international experience includes launching new innovations, growing business internationally, negotiating strategic cooperations and product licensing as well as leading small to medium high tech corporations.
Trude Tingvoll
Chief Business Officer
Trude holds a Master of Business and Economics and an Executive MBA from BI, Norwegian Business School, Norway. She has more than 20 years of expertise in the Pharmaceutical and Biotech industry at Global, European and National level within alliance management, business development, building corporate and brand strategies, new product launches and sales development for companies such as Pfizer, UCB, and AstraZeneca. Prior to joining Respinor, Trude served as Global Director of Business Development and Alliance Management for Photocure, in Norway. She has been Chief Business Officer of Respinor since April 2018.
Adam Dowrick
Clinical Manager
Ph.D Epidemiology from Monash University, Australia, has over 10 years’ experience in the design, management and presentation of clinical studies conducted in tertiary hospitals and has published over 30 articles in a number of different medical specialties.
Torgeir Hamsund
Chief Production Officer
Torgeir have over 30 years of experience in industrializing products. He has specialized in bringing products from idea to mass production within consumer, medical and military industries. Previously he has worked as VP R&D in Spinchip Diagnostics, Project Manager R&D at Tronrud Engineering, CEO at 360 Design and Depute Manager at Abry Design. He holds a BaH in Industrial Design from Newcastle University UK. He has been Chief Production Officer of Respinor since August 2018.
Morten Eriksen
R&D Manager
MD from University of Oslo. Extensive experience in the intersection of technology and medicine. Has contributed and initiated over 20 patents and patent applications in his work for Nycomed, OUS and Volusense. He has been instrumental in the successful development of Respinor’s product.
Monica Weiseth
Director RA & QA
Monica holds a MSc in organic chemistry from the Norwegian University of Science and Technology (NTNU). She has more than 20 years of experience in quality and regulatory affairs, product development, global product registrations including CE marking and FDA 510k approvals. Previously she worked for Alere Technologies a global IVD medical device manufacturer. Prior to joining RESPINOR, Monica served as head of Quality in certification body/notified body DNV GL Presafe.
Board of Directors
Fredrik C. Schreuder
Chairman of the Board
Fredrik C Schreuder was elected Chairman of the Board of Directors of Respinor AS at the Annual Meeting on June 22nd 2017.
He has most of his academic education from the United States. After undergraduate studies at the University of Wisconsin, he completed his MBA at the Harvard Business School in 1963. Subseqently he served as research associate in International Business at IMEDE Management Development Institute in Lausanne, Switzerland.
Upon his return to Norway, he has served in leadership positions at Christiania Bank og Kreditkasse and Øivind Lorentzen AS, prior to joining Hafslund ASA in 1982 as Chief Financial Officer and member of the Board of Management. He played an active role in the acquisition of Nycomed in 1985 and he managed Hafslund’s investment portfolio.
In 1989 he formed his own investment management company, Medical Venture Management AS, and he managed two venture capital funds, investing in medical technology and life science companies. These activities had a distinctly international focus, and he became well acquainted with these industries, both in Europe and the United States.
Mr. Schreuder served as Chairman of the Board of Directors of the Norwegian medical radiology company, Algeta AS, in its early formative years, and he is a seasoned investor in a number of medically related companies in Norway and abroad.
Fredrik C Schreuder was a founder and the first Chairman of the Norwegian Society of Financial Analysts, of which he is an honorary member. He has also served on the Board of the European Federation of Financial Analyst Societies, and he was for several years Chairman of the Harvard Business School Club Norway.
Aage Bryn
Board Member
Lic.oec HSG (MBA) from Hochschule St. Gallen, CH, Director.
Aage is today a real-estate and life science investor and the largest shareholder in Respinor. He worked for 10 years as a management consultant and as “Management for Hire” with Asbjørn Habberstad AS in the Nordic countries. He was later Owner and CEO of the largest privately owned importer of agricultural machinery in Norway.
Jan Fikkan
Board member
Jan has more than 20 years of experience in various executive roles in the international pharmaceutical industry. He was running the Japan region for GE Healthcare for 10 years – a role including building infrastructure on the ground while optimise the business through Strategic Alliance and JV structures. He had full P&L responsibility for a $130m business. Jan has also been running the global pharma R&D operations in GE Healthcare including a $50m development portfolio and project/portfolio teams in UK, USA and Norway. Jan left GE in Oct 2014 as the President for the 800 employee Norwegian organisation. Beside being board member in Respinor, Jan is also Chairman of the board of Mentis Cura AS and Phoenix Solutions AS and board member of Oxy Solutions AS and Spinchip Diagnostics AS.
Marco Renoldi
Board member
Marco is Chief Business Officer in Nordic Nanovector since November 2014. Prior to joining Nordic Nanovector, Marco served as SVP & Chief Commercial Officer at Shionogi Ltd., from July 2012 to October 2014. From January 2009 to June 2012 he served as Executive Director & International Franchise Head, Oncology-Hematology at Amgen, where he had previously led the Italian affiliate as Managing Director. Prior to joining Amgen, Marco held national, regional and global R&D and business roles at Novartis, Searle-Monsanto and Pharmacia. In his 28-year industry experience Marco has developed product lines and businesses, including start-ups. Marco holds a medical degree from the University of Milan and an MBA from Fondazione IDI/Assolombarda. Marco is an Italian citizen and he resides in Switzerland.
Partners
Ullevål Hospital (OUS), Pulmonary section Leading center for investigation and treatments of patients with diseases and failure in lung function.
Buskerud and Vestfold University College (HBV), part of the Centre for Innovative Ultrasound Solutions (CIUS).
BDK Industrial Products Ltd. UK, a top class developer and manufacturer of medical tapes.
Oslo Medtech is a health technology cluster, dedicated to accelerating and supporting the development of new medtech, eHealth products, services and innovative solutions for the Norwegian and global health care market.
Grants & recognitions
Respinor was ranked number 1st of 237 applications in the Horizon 2020 phase II SME instrument call. The company will use the EU funding to develop a market ready product and to conduct a randomised clinical trial to obtain clinical evidence of its use in the weaning process.
Horizon 2020 is the biggest EU Research and Innovation programme with nearly €80 billion of funding available over 7 years (2014 to 2020) – in addition to the private investment that this money will attract. It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.
Respinor was awarded funding for 2017 from FORNY 2020 to perform activities bringing the company to clinical and technical verification.
FORNY2020 aims at creating value and benefits for society from research results. This is done by funding the Norwegian technology transfer offices (TTOs) and projects in need of proof-of-concept.
Respinor was awarded seed funding from Inven2. Through this investment, Inven2 became the third largest shareholder in Respinor.
Inven2 is owned by the University of Oslo and Oslo University Hospital and aims to support the commercialization of Norwegian innovations.
Respinor was awarded funding from Innovation Norway for exploring market opportunities and the commercial potential of our product idea. The support was of great help to the company in the early phase of development.
Innovation Norway is the Norwegian Government’s most important instrument for innovation and development of Norwegian enterprises and industry. We support companies in developing their competitive advantage and to enhance innovation.
Respinor (in collaboration with K8 Industrial Design) was awarded funding from Design and Architecture Norway (DOGA) as part of their Design-driven Innovation Program (DIP).
Under this programme, DOGA aims to facilitate the involvement of designers during the idea phase of innovation projects so that final products have a greater chance of meeting the needs of the user.
Respinor ranked 3rd of 323 applicants for Eurostars funding. This funding was used to support the development of the prototype device.
Eurostars is a joint programme between EUREKA and the European Commission for SMEs to foster international collaboration to support the rapid development of innovative projects.